AARTIPHARM
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
This data is currently unavailable for this company.
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
(In Cr.) |
---|
(In Cr.) | ||||
---|---|---|---|---|
This data is currently unavailable for this company. |
(In %) |
---|
(In Cr.) |
---|
Financial Year (In Cr.) |
---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
India's Aarti Pharmalabs falls on quarterly profit decline
** Shares of Aarti Pharmalabs AARP.NS drop 7% to 796 rupees, their lowest point since May 19
** Stock marks steepest intraday pct loss since April 4
** The Indian drugmaker posts 10.7% y/y decline in June-quarter consol net profit; consol revenue from operations drops nearly 30.5% y/y
** More than 607,127 shares change hands, 2.3x of 30-day avg
** Stock up 16%, YTD
(Reporting by Rudra Pratap Singh in Bengaluru)
** Shares of Aarti Pharmalabs AARP.NS drop 7% to 796 rupees, their lowest point since May 19
** Stock marks steepest intraday pct loss since April 4
** The Indian drugmaker posts 10.7% y/y decline in June-quarter consol net profit; consol revenue from operations drops nearly 30.5% y/y
** More than 607,127 shares change hands, 2.3x of 30-day avg
** Stock up 16%, YTD
(Reporting by Rudra Pratap Singh in Bengaluru)
Aarti Pharmalabs June-Quarter Consol Net Profit 495 Million Rupees
Aug 12 (Reuters) - Aarti Pharmalabs Ltd AARP.NS:
AARTI PHARMALABS JUNE-QUARTER CONSOL NET PROFIT 495 MILLION RUPEES
AARTI PHARMALABS JUNE-QUARTER CONSOL NET REVENUE FROM OPERATIONS 3.86 BILLION RUPEES
Source text: ID:nBSE2xmKkF
Further company coverage: AARP.NS
(([email protected];;))
Aug 12 (Reuters) - Aarti Pharmalabs Ltd AARP.NS:
AARTI PHARMALABS JUNE-QUARTER CONSOL NET PROFIT 495 MILLION RUPEES
AARTI PHARMALABS JUNE-QUARTER CONSOL NET REVENUE FROM OPERATIONS 3.86 BILLION RUPEES
Source text: ID:nBSE2xmKkF
Further company coverage: AARP.NS
(([email protected];;))
Aarti Pharmalabs Executes Addendum To Agreement With Bandodkars
April 1 (Reuters) - Aarti Pharmalabs Ltd AARP.NS:
EXECUTES ADDENDUM TO AGREEMENT WITH BANDODKARS
Source text: ID:nBSE73MBzL
Further company coverage: AARP.NS
(([email protected];;))
April 1 (Reuters) - Aarti Pharmalabs Ltd AARP.NS:
EXECUTES ADDENDUM TO AGREEMENT WITH BANDODKARS
Source text: ID:nBSE73MBzL
Further company coverage: AARP.NS
(([email protected];;))
Aarti Pharmalabs Enters Share Subscription Agreement With Pro-ZEAL Green Power
Jan 9 (Reuters) - Aarti Pharmalabs Ltd AARP.NS:
AARTI PHARMALABS - ENTERS SHARE SUBSCRIPTION AGREEMENT WITH PRO-ZEAL GREEN POWER
AARTI PHARMALABS LTD - TO ACQUIRE 26.25% EQUITY IN PRO-ZEAL GREEN POWER
Source text: ID:nBSE8FHX7g
Further company coverage: AARP.NS
(([email protected];;))
Jan 9 (Reuters) - Aarti Pharmalabs Ltd AARP.NS:
AARTI PHARMALABS - ENTERS SHARE SUBSCRIPTION AGREEMENT WITH PRO-ZEAL GREEN POWER
AARTI PHARMALABS LTD - TO ACQUIRE 26.25% EQUITY IN PRO-ZEAL GREEN POWER
Source text: ID:nBSE8FHX7g
Further company coverage: AARP.NS
(([email protected];;))
India's Aarti Pharmalabs falls on order to shut plant
** Shares of Aarti Pharmalabs AARP.NS fall 3% to 672 rupees
** The pharma co says Gujarat state's pollution control board ordered closure of operations at Valsad plant due to environmental damage
** AARP's down 1% for the week; had gained 36% in 2024
($1 = 85.7800 Indian rupees)
(Reporting by Ashna Teresa Britto in Bengaluru)
** Shares of Aarti Pharmalabs AARP.NS fall 3% to 672 rupees
** The pharma co says Gujarat state's pollution control board ordered closure of operations at Valsad plant due to environmental damage
** AARP's down 1% for the week; had gained 36% in 2024
($1 = 85.7800 Indian rupees)
(Reporting by Ashna Teresa Britto in Bengaluru)
Aarti Pharmalabs June-Quarter Consol Net Profit 554.5 Mln Rupees
Aug 5 (Reuters) - Aarti Pharmalabs Ltd AARP.NS:
AARTI PHARMALABS LTD JUNE-QUARTER CONSOL NET PROFIT 554.5 MILLION RUPEES
AARTI PHARMALABS LTD JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 5.55 BILLION RUPEES
Source text for Eikon: [ID:]
Further company coverage: AARP.NS
(([email protected];))
Aug 5 (Reuters) - Aarti Pharmalabs Ltd AARP.NS:
AARTI PHARMALABS LTD JUNE-QUARTER CONSOL NET PROFIT 554.5 MILLION RUPEES
AARTI PHARMALABS LTD JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 5.55 BILLION RUPEES
Source text for Eikon: [ID:]
Further company coverage: AARP.NS
(([email protected];))
Aarti Pharmalabs Got Order From Pollution Board For Closure Of Manufacturing Facilities At Dombivli Plant
May 31 (Reuters) - Aarti Pharmalabs Ltd AARP.NS:
AARTI PHARMALABS - RECEIVED ORDER FROM POLLUTION BOARD FOR CLOSURE OF MANUFACTURING FACILITIES AT CO'S DOMBIVLI PLANT
AARTI PHARMALABS LTD - CO WILL SHUT PRODUCTION OPERATION WITH EFFECT FROM MAY 31, 2024
AARTI PHARMALABS LTD - REASONS FOR CLOSURE - COMPLIANCE WITH MPCB INTERIM DIRECTIONS ON FUEL USAGE
Source text for Eikon: ID:nBSE8bGxly
Further company coverage: AARP.NS
(([email protected];))
May 31 (Reuters) - Aarti Pharmalabs Ltd AARP.NS:
AARTI PHARMALABS - RECEIVED ORDER FROM POLLUTION BOARD FOR CLOSURE OF MANUFACTURING FACILITIES AT CO'S DOMBIVLI PLANT
AARTI PHARMALABS LTD - CO WILL SHUT PRODUCTION OPERATION WITH EFFECT FROM MAY 31, 2024
AARTI PHARMALABS LTD - REASONS FOR CLOSURE - COMPLIANCE WITH MPCB INTERIM DIRECTIONS ON FUEL USAGE
Source text for Eikon: ID:nBSE8bGxly
Further company coverage: AARP.NS
(([email protected];))
Aarti Pharmalabs- Expect EBITDA Growth Of About 10-12% In FY25
May 15 (Reuters) - Aarti Pharmalabs Ltd AARP.NS:
AARTI PHARMALABS LTD- COMMERCIALIZATION OF ATALI PROJECT EXPANSION EXPECTED IN Q4FY25
AARTI PHARMALABS LTD- EXPECT EBITDA GROWTH OF ABOUT 10-12% IN FY25
AARTI PHARMALABS LTD- AIM TO ACHIEVE LONG-TERM GOAL OF OVER 15% ANNUAL GROWTH IN NEXT 3 YEARS
Source text for Eikon: ID:nBSE6Dv9rD
Further company coverage: AARP.NS
(([email protected];))
May 15 (Reuters) - Aarti Pharmalabs Ltd AARP.NS:
AARTI PHARMALABS LTD- COMMERCIALIZATION OF ATALI PROJECT EXPANSION EXPECTED IN Q4FY25
AARTI PHARMALABS LTD- EXPECT EBITDA GROWTH OF ABOUT 10-12% IN FY25
AARTI PHARMALABS LTD- AIM TO ACHIEVE LONG-TERM GOAL OF OVER 15% ANNUAL GROWTH IN NEXT 3 YEARS
Source text for Eikon: ID:nBSE6Dv9rD
Further company coverage: AARP.NS
(([email protected];))
India's Aarti Pharmalabs hits record high on Q4 profit jump
** Shares of Aarti Pharmalabs AARP.NS up as much as 11.9% to a record high of 581.95 rupees
** The active pharmaceutical ingredients (API) maker on Monday reported a 52.2% Y/Y jump in its March-qtr consolidated net profit to 652.5 mln rupees ($7.8 mln)
** Revenue from operations rose 4.3% Y/Y
** AARP on track for a third consecutive session of gains, if trends hold
** Stock posts biggest intraday pct gain since April 2023
** More than 3.4 mln shares change hands by 11:03 a.m. IST, 16.3x the 30-day moving avg
** Including session's move, stock is up 14.4% YTD
($1 = 83.5020 Indian rupees)
(Reporting by Navamya Ganesh Acharya in Bengaluru)
(([email protected]; +91 8805175330 ;))
** Shares of Aarti Pharmalabs AARP.NS up as much as 11.9% to a record high of 581.95 rupees
** The active pharmaceutical ingredients (API) maker on Monday reported a 52.2% Y/Y jump in its March-qtr consolidated net profit to 652.5 mln rupees ($7.8 mln)
** Revenue from operations rose 4.3% Y/Y
** AARP on track for a third consecutive session of gains, if trends hold
** Stock posts biggest intraday pct gain since April 2023
** More than 3.4 mln shares change hands by 11:03 a.m. IST, 16.3x the 30-day moving avg
** Including session's move, stock is up 14.4% YTD
($1 = 83.5020 Indian rupees)
(Reporting by Navamya Ganesh Acharya in Bengaluru)
(([email protected]; +91 8805175330 ;))
Aarti Pharmalabs Ltd - Dividend 1 Rupees Per Share
Aarti Pharmalabs Ltd AARP.NS:
AARTI PHARMALABS LTD - DIVIDEND 1 RUPEES PER SHARE
Source text for Eikon: ID:nNSE3p93yj
Further company coverage: AARP.NS
Aarti Pharmalabs Ltd AARP.NS:
AARTI PHARMALABS LTD - DIVIDEND 1 RUPEES PER SHARE
Source text for Eikon: ID:nNSE3p93yj
Further company coverage: AARP.NS
Aarti Pharmalabs Dec-Quarter Consol Net Profit Rises
Feb 7 (Reuters) - Aarti Pharmalabs Ltd AARP.NS:
DEC-QUARTER CONSOL NET PROFIT 527.6 MILLION RUPEES VERSUS 476.9 MILLION RUPEES YEAR AGO
DEC-QUARTER CONSOL REVENUE FROM OPERATIONS 4.49 BILLION RUPEES VERSUS 4.72 BILLION RUPEES YEAR AGO
Source text for Eikon: ID:nBSE11qXTb
Further company coverage: AARP.NS
(([email protected];))
Feb 7 (Reuters) - Aarti Pharmalabs Ltd AARP.NS:
DEC-QUARTER CONSOL NET PROFIT 527.6 MILLION RUPEES VERSUS 476.9 MILLION RUPEES YEAR AGO
DEC-QUARTER CONSOL REVENUE FROM OPERATIONS 4.49 BILLION RUPEES VERSUS 4.72 BILLION RUPEES YEAR AGO
Source text for Eikon: ID:nBSE11qXTb
Further company coverage: AARP.NS
(([email protected];))
India's Aarti Pharmalabs Sept-Quarter Consol Net Profit Rises
Nov 7 (Reuters) - Aarti Pharmalabs Ltd AARP.NS:
INDIA'S AARTI PHARMALABS SEPT-QUARTER CONSOL NET PROFIT 518 MILLION RUPEES VERSUS PROFIT 510.9 MILLION RUPEES
AARTI PHARMALABS SEPT-QUARTER CONSOL NET REVENUE FROM OPERATIONS 4.4 BILLION RUPEES VERSUS 5.31 BILLION RUPEES
Source text for Eikon: [ID:]
Further company coverage: AARP.NS
(([email protected];))
Nov 7 (Reuters) - Aarti Pharmalabs Ltd AARP.NS:
INDIA'S AARTI PHARMALABS SEPT-QUARTER CONSOL NET PROFIT 518 MILLION RUPEES VERSUS PROFIT 510.9 MILLION RUPEES
AARTI PHARMALABS SEPT-QUARTER CONSOL NET REVENUE FROM OPERATIONS 4.4 BILLION RUPEES VERSUS 5.31 BILLION RUPEES
Source text for Eikon: [ID:]
Further company coverage: AARP.NS
(([email protected];))
Aarti Pharmalabs Expects EBIDTA Growth To Be About 12%-17% Over Next 2-3 Years
June 26 (Reuters) - Aarti Pharmalabs Ltd AARP.NS:
AARTI PHARMALABS LTD - EXPECTING EBIDTA GROWTH TO BE ABOUT 12%-17% OVER NEXT 2-3 YEARS
Source text for Eikon: ID:nNSEbpqlWM
Further company coverage: AARP.NS
(([email protected];))
June 26 (Reuters) - Aarti Pharmalabs Ltd AARP.NS:
AARTI PHARMALABS LTD - EXPECTING EBIDTA GROWTH TO BE ABOUT 12%-17% OVER NEXT 2-3 YEARS
Source text for Eikon: ID:nNSEbpqlWM
Further company coverage: AARP.NS
(([email protected];))
India's Aarti Pharmalabs March-Quarter Consol Net Profit Falls
May 12 (Reuters) - Aarti Pharmalabs Ltd AARP.NS:
MARCH-QUARTER CONSOL NET PROFIT 428.7 MILLION RUPEES VERSUS 488.7 MILLION RUPEES
MARCH-QUARTER CONSOL NET REVENUE FROM OPERATIONS 4.85 BILLION RUPEES VERSUS 4.60 BILLION RUPEES
Source text for Eikon: [ID:]
Further company coverage: AARP.NS
(([email protected];))
May 12 (Reuters) - Aarti Pharmalabs Ltd AARP.NS:
MARCH-QUARTER CONSOL NET PROFIT 428.7 MILLION RUPEES VERSUS 488.7 MILLION RUPEES
MARCH-QUARTER CONSOL NET REVENUE FROM OPERATIONS 4.85 BILLION RUPEES VERSUS 4.60 BILLION RUPEES
Source text for Eikon: [ID:]
Further company coverage: AARP.NS
(([email protected];))
Events:
Dividend
Dividend
Dividend
Dividend
Dividend
More Small Cap Ideas
See similar 'Small' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Aarti Pharmalabs do?
Aarti Pharmalabs Limited is a leading Indian manufacturer of Pharmaceuticals and Nutraceuticals, focusing on Active Pharmaceutical Ingredients and xanthine derivatives, leveraging process chemistry expertise and scale-up engineering.
Who are the competitors of Aarti Pharmalabs?
Aarti Pharmalabs major competitors are Shilpa Medicare, Supriya Lifescience, Aarti Drugs, Acutaas Chemicals, Alivus Life Sciences, IOL Chem & Pharma, Solara Active Pharma. Market Cap of Aarti Pharmalabs is ₹7,455 Crs. While the median market cap of its peers are ₹5,641 Crs.
Is Aarti Pharmalabs financially stable compared to its competitors?
Aarti Pharmalabs seems to be less financially stable compared to its competitors. Altman Z score of Aarti Pharmalabs is 7.23 and is ranked 4 out of its 8 competitors.
Does Aarti Pharmalabs pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Aarti Pharmalabs latest dividend payout ratio is 16.64% and 3yr average dividend payout ratio is 12.85%
How has Aarti Pharmalabs allocated its funds?
Companies resources are allocated to majorly productive assets like Plant & Machinery and unproductive assets like Capital Work in Progress
How strong is Aarti Pharmalabs balance sheet?
Balance sheet of Aarti Pharmalabs is strong. It shouldn't have solvency or liquidity issues.
Is the profitablity of Aarti Pharmalabs improving?
The profit is oscillating. The profit of Aarti Pharmalabs is ₹268 Crs for TTM, ₹272 Crs for Mar 2025 and ₹217 Crs for Mar 2024.
Is the debt of Aarti Pharmalabs increasing or decreasing?
Yes, The net debt of Aarti Pharmalabs is increasing. Latest net debt of Aarti Pharmalabs is ₹379 Crs as of Mar-25. This is greater than Mar-24 when it was ₹216 Crs.
Is Aarti Pharmalabs stock expensive?
Yes, Aarti Pharmalabs is expensive. Latest PE of Aarti Pharmalabs is 27.98, while 3 year average PE is 24.1. Also latest EV/EBITDA of Aarti Pharmalabs is 16.93 while 3yr average is 15.79.
Has the share price of Aarti Pharmalabs grown faster than its competition?
Aarti Pharmalabs has given lower returns compared to its competitors. Aarti Pharmalabs has grown at ~35.69% over the last 2yrs while peers have grown at a median rate of 36.97%
Is the promoter bullish about Aarti Pharmalabs?
Promoters seem not to be bullish about the company and have been selling shares in the open market. Latest quarter promoter holding in Aarti Pharmalabs is 43.72% and last quarter promoter holding is 44.29%
Are mutual funds buying/selling Aarti Pharmalabs?
The mutual fund holding of Aarti Pharmalabs is increasing. The current mutual fund holding in Aarti Pharmalabs is 0.9% while previous quarter holding is 0.78%.